Home/Filings/4/0000897069-24-000919
4//SEC Filing

Bigora Sian 4

Accession 0000897069-24-000919

CIK 0001533743other

Filed

Apr 11, 8:00 PM ET

Accepted

Apr 12, 4:52 PM ET

Size

9.0 KB

Accession

0000897069-24-000919

Insider Transaction Report

Form 4
Period: 2024-01-01
Bigora Sian
Chief Development Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2024-01-01+1,67521,826 total
  • Tax Payment

    Common Stock

    2024-01-01$2.79/sh368$1,02721,458 total
  • Exercise/Conversion

    Restricted Stock Units

    2024-01-011,67522,139 total
    Exercise: $0.00Common Stock (1,675 underlying)
Holdings
  • Common Stock

    (indirect: By LLC)
    6,668
Footnotes (2)
  • [F1]Distribution of vested restricted shares.
  • [F2]Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Documents

1 file

Issuer

Processa Pharmaceuticals, Inc.

CIK 0001533743

Entity typeother

Related Parties

1
  • filerCIK 0001799365

Filing Metadata

Form type
4
Filed
Apr 11, 8:00 PM ET
Accepted
Apr 12, 4:52 PM ET
Size
9.0 KB